* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Fact Sheet - Franklin Templeton Investments
Special-purpose acquisition company wikipedia , lookup
Corporate venture capital wikipedia , lookup
History of investment banking in the United States wikipedia , lookup
Environmental, social and corporate governance wikipedia , lookup
Leveraged buyout wikipedia , lookup
Investment banking wikipedia , lookup
Private equity in the 2000s wikipedia , lookup
Money market fund wikipedia , lookup
Private equity in the 1980s wikipedia , lookup
Private equity wikipedia , lookup
Socially responsible investing wikipedia , lookup
Private money investing wikipedia , lookup
Early history of private equity wikipedia , lookup
Private equity secondary market wikipedia , lookup
Mutual fund wikipedia , lookup
Franklin Templeton Investment Funds Sector Equity 30.06.2017 Franklin Biotechnology Discovery Fund Fund Fact Sheet Performance Fund Overview Base Currency for Fund USD Total Net Assets (USD) 2,409 million Fund Inception Date 03.04.2000 Number of Issuers 100 Benchmark NASDAQ Biotechnology Index Morningstar Category™ Sector Equity Biotechnology Minimum Investment Share Class Initial Subsequent A (acc) USD USD 1,000 USD 500 A (acc) SGD SGD 1,000 SGD 500 Performance over 5 Years in Share Class Currency (%) Franklin Biotechnology Discovery Fund A (acc) USD 300 260 220 180 140 100 60 06/12 12/12 06/13 12/13 06/14 12/14 06/15 12/15 Cumulative The Fund aims to achieve capital appreciation by investing principally in equity securities of biotechnology companies and discovery research firms mainly located in the US. Fund Management Evan McCulloch, CFA: United States Steve Kornfeld, CFA: United States 06/16 12/16 06/17 Performance in Share Class Currency (%) Summary of Investment Objective Annualised A (acc) USD After Sales Charge* Benchmark in USD 1 Yr 22.04 15.93 20.50 3 Yrs 19.81 13.82 20.87 5 Yrs 119.38 108.41 141.34 Since Incept 209.11 193.66 204.67 A (acc) SGD After Sales Charge* Benchmark in SGD 24.75 18.51 23.18 32.31 25.69 33.48 138.28 126.36 162.25 209.99 194.49 254.35 3 Yrs 6.21 4.41 6.52 Since 5 Yrs Incept 17.02 6.76 15.82 6.45 19.27 6.68 9.78 7.92 10.10 18.97 17.75 21.27 12.40 11.80 13.96 References to indices are made for comparative purposes only and are provided to represent the investment environment existing during the time periods shown. Ratings - A (acc) USD Overall Morningstar Rating™: Asset Allocation Equity Cash & Cash Equivalents NASDAQ Biotechnology Index % 98.76 1.24 Top Ten Holdings (% of Total) Issuer Name CELGENE CORP ALEXION PHARMACEUTICALS INC INCYTE CORP REGENERON PHARMACEUTICALS INC BIOGEN INC GILEAD SCIENCES INC ILLUMINA INC CLOVIS ONCOLOGY INC VERTEX PHARMACEUTICALS INC TESARO INC 10.43 7.68 5.89 5.79 Fund Measures P/E to Growth Historical 3 Yr Sales Growth Estimated 3-5 Yr EPS Growth Price to Earnings (12-mo Forward) Standard Deviation (5 Yrs) 1.45x 30.36% 21.22% 19.46x 23.97% 4.76 4.51 4.15 4.02 3.64 3.53 Share Class Information (For a full list of available share classes, please visit www.franklintempleton.com.sg.) Fees Incept Max. Sales Max. Annual Mgmt. Share Class Date NAV TER (%) Charge (%) Charge (%) Fee (%) A (acc) USD 03.04.2000 USD 30.91 1.81 5.00 1.50 1.00 A (acc) SGD 25.10.2007 SGD 31.00 1.81 5.00 1.50 1.00 Max. Maint. Charge (%) 0.50 0.50 Additional Share Class Information Dividends Share Class A (acc) USD A (acc) SGD Incept Date 03.04.2000 25.10.2007 Templeton Asset Management Ltd 7 Temasek Boulevard #38-03 Subscription Type Cash Cash/SRS Suntec Tower One Frequency N/A N/A Fund Identifiers Last Paid Date N/A N/A Singapore 038987 Last Paid Amount N/A N/A Bloomberg ID TEMBDAI LX TEBTASG LX Phone (65) 6241 2662 ISIN LU0109394709 LU0320765992 Franklin Biotechnology Discovery Fund 30.06.2017 Composition of Fund Market Capitalisation Breakdown in USD <2.0 Billion 2.0-5.0 Billion 5.0-10.0 Billion 10.0-25.0 Billion 25.0-50.0 Billion >50.0 Billion N/A % of Equity 22.73 15.60 7.29 2.81 21.62 29.03 0.92 Important Information Copyright© 2017. Franklin Templeton Investments. All Rights Reserved. Issued by Templeton Asset Management Ltd. Registration No.(UEN) 199205211E. This document is for information only and does not constitute investment advice or a recommendation and was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. The value of investments and the income from them can go down as well as up and you may not get back the full amount that you invested. Past performance is not an indicator or a guarantee of future performance. Subscriptions may only be made on the basis of the most recent Prospectus and Product Highlights Sheet which is available at Templeton Asset Management Ltd or our authorised distributors. Potential investor should read the details of the Prospectus and Product Highlights Sheet before deciding to subscribe for or purchase the Fund. This shall not be construed as the making of any offer or invitation to anyone in any jurisdiction in which such offer is not authorised or in which the person making such offer is not qualified to do so or to anyone to whom it is unlawful to make such an offer. In particular, this Fund is not available to U.S. Persons and Canadian residents. Investors may wish to seek advice from a financial adviser before making a commitment to invest in shares of the Fund. In the event an investor chooses not to seek advice from a financial adviser, he/she should consider whether the Fund is suitable for him/her. Performance: Performance details provided are in the share class currency, based on NAV-NAV and include reinvested dividends. Performances of different share classes will vary. Please refer to the Fund Manager for more information. Fund Management: CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. Ratings: © Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. After Sales Charge*: Calculated based on initial sales charge of 5%; or 0% for Money Market Funds. Top Ten Holdings: These securities do not represent all of the securities purchased, sold or recommended and readers should not assume that investment in the securities listed was or will be profitable. Fund manager reserves the right to withhold release of portfolio holdings information. All portfolio holdings are subject to change. Copyright© 2017. Franklin Templeton Investments. All Rights Reserved. www.franklintempleton.com.sg